It was further identified that CML cells expressed a chimeric bcr:Aabl mRNA [4] and in 1986 David Baltimore and colleagues identified that a CML-associated 210-kilodalton phosphoprotein that cross reacted with v-abl-specific antisera was indeed the protein product of this fusion gene transcript [5]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.